Population genotyping only from July 1 st , 2010 Analysis are performed in 3 centers (Gent, Leuven, UCL Brussels) Only for patients for whom MVC initiation is considered (fulfilling criteria for reimbursement) Home ‐ made sequencing methods with ABI Big Dye terminator kits and ABI instrumentation (Gent ‐ UCL/Leuven – exchange of PCR failing samples). Plasma RNA as standard, proviral DNA if VL <500 c/ml Triplicate testing, both for RNA and DNA (evaluation period) Manual proofreading (ABI software/ SmartGene IDNS & RECall) Report: %FPR of triplicate tests with interpretation following ‘German recommendations’.
2,0 1,8 1,6 Log FPR ‐ proviral DNA 1,4 1,2 1,0 0,8 0,6 0,4 0,2 0,0 0,0 0,2 0,4 0,6 0,8 1,0 1,2 1,4 1,6 1,8 2,0 Log FPR ‐ plasma viral RNA
Evaluation in collaboration with AM Wensing and R Paredes. Results are submitted as abstract to EHDRW 2010 101 samples (RNA and DNA) ‐ 265 results Range of different VL X4 prediction 10% FPR: 28% (+15% using 20% FPR) – single testing RNA samples ‐ triplicate testing: discordant predictions of 8.6% (10% FPR) and 12.1% (20% FPR) DNA samples: 9.3% and 18.6% respectively Single testing detected X4 in 24 (24%) of patients (10% FPR). Duplicate testing: 2 additional patients were scored X4 Triplicate testing: 2+1 additional patients were scored X4 Independent of viral load
24 selected samples. Concordant X4: 10; Concordant R5: 9; Discordant: 5 p p RNA RNA RNA VL CD4 %FPR1 %FPR2 %FPR3 369 335000 93 6,9 6.9 ‐ 6.9 ‐ 625 >100000 60 8,7 8.7 ‐ 8.7 ‐ 415 9850 315 9,0 9.0 ‐ 9.0 ‐ 33 80600 21 7,8 6.0+ 6.6+ 9529 134000 287 5,0 2,9 6,0 941 100000 262 1,7 1.7+ 1.7+ 572 306000 223 7,8 7.8 ‐ 7.8 ‐ 8917 37600 538 9,9 23,6 9.9+ 9221 1318 414 31,6 33,7 33,7 9228 42800 205 17,1 17.1 ‐ 17.1 ‐ 9522 >100000 63 8,5 7.4+ 7.4+ 614 46600 908 33,9 33.9+ 33.9+ 621 153000 151 10,9 10.9 ‐ 10.9 ‐ 526 54300 163 12.5 5.3+ 7.8+ 891 1690 282 74,4 74.4 74.5 9322 374000 7 9,3 10.2+ 16.6+ 481 1300 260 19,5 ‐ 19,5 ‐ 19,5 ‐ 49 20700 161 6,9+ 5,8+ 15,7 ‐ 493 200000 104 3,7 ‐ 2,4+ 6,9 ‐ 595 162000 34 10,8 ‐ 3,9+ 3,9+ 514 13800 192 90,3 90,3 90,3 618 8730 381 3,7 3,7 3,7 635 >100000 232 32,7 28,8 32,7 669 8350 284 15,4 15,4 15,4
RNA RNA RNA %FPR1 %FPR2 %FPR3 9,9 23,6 9.9+ 8,5 7.4+ 7.4+ 12.5 5.3+ 7.8+ 9,3 10.2+ 16.6+ 6,9+ 5,8+ 15,7 ‐ 3,7 ‐ 2,4+ 6,9 ‐ 10,8 ‐ 3,9+ 3,9+ 3,7 3,7 3,7 Clinical outcome?
Recommend
More recommend
